Dodge & Cox Has $1.65 Billion Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Dodge & Cox raised its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,321,316 shares of the biopharmaceutical company’s stock after buying an additional 9,381 shares during the quarter. Dodge & Cox owned 2.11% of Regeneron Pharmaceuticals worth $1,653,543,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. OFI Invest Asset Management bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth about $28,000. Rakuten Securities Inc. grew its stake in Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 15 shares during the period. Avalon Trust Co acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $36,000. Crowley Wealth Management Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth $36,000. Finally, Private Wealth Management Group LLC increased its stake in Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 39 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $571.06 on Tuesday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $525.99 and a twelve month high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock’s 50 day moving average is $657.03 and its 200 day moving average is $749.93. The company has a market capitalization of $62.43 billion, a P/E ratio of 14.92, a PEG ratio of 2.34 and a beta of 0.44.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same period last year, the business earned $11.86 EPS. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. On average, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.62%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the company. The Goldman Sachs Group dropped their target price on Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a “buy” rating on the stock in a report on Monday. Citigroup lowered their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Truist Financial dropped their price target on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Piper Sandler decreased their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Finally, Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, eighteen have assigned a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $964.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.